Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers

AIMS: Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation‐related cardiovascular disease. Here, we investigated the safety, tolerability and pharmacokinetics of the myeloperoxidase inhibitor, AZD4831. METHODS: In this randomized, sin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Clin Pharmacol
Hauptverfasser: Gan, Li‐Ming, Lagerström‐Fermér, Maria, Ericsson, Hans, Nelander, Karin, Lindstedt, Eva‐Lotte, Michaëlsson, Erik, Kjaer, Magnus, Heijer, Maria, Whatling, Carl, Fuhr, Rainard
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2019
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6422671/
https://ncbi.nlm.nih.gov/pubmed/30618054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13855
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge